1205-56-7 Usage
Description
2-bromo-4-nitropropiophenone, also known as BNPP, is a chemical compound with the formula C9H8BrNO3. It is a yellow solid that is commonly used as an intermediate in the synthesis of pharmaceuticals and organic compounds.
Used in Pharmaceutical Industry:
2-bromo-4-nitropropiophenone is used as a chemical intermediate for the synthesis of various pharmaceuticals and organic compounds. Its versatility in undergoing nucleophilic substitution, reduction, and rearrangement reactions allows for the production of a wide range of derivatives.
Used in Dye Production:
2-bromo-4-nitropropiophenone is used as a precursor in the production of dyes and other industrial chemicals. Its reactivity and potential hazards necessitate careful handling and storage in a controlled laboratory setting by trained professionals.
Check Digit Verification of cas no
The CAS Registry Mumber 1205-56-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,2,0 and 5 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1205-56:
(6*1)+(5*2)+(4*0)+(3*5)+(2*5)+(1*6)=47
47 % 10 = 7
So 1205-56-7 is a valid CAS Registry Number.
1205-56-7Relevant articles and documents
READ-THROUGH INDUCER AND PHARMACEUTICAL USE THEREOF
-
Paragraph 0306-0310, (2020/08/04)
PROBLEM TO BE SOLVED: To provide a novel read-through inducer. SOLUTION: The present invention relates to a compound represented by the general formula (I) [each symbol in the formula is as described in the specification] or a pharmaceutically acceptable
INDOLE DERIVATIVES AS CRAC MODULATORS
-
Page/Page column 45, (2012/01/30)
Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).
Kinase inhibitors
-
Page 34, (2010/02/03)
The present application is directed to pyrazolopyrirnidine and furopyrimidine analogs of the formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.
